RevealDx Announces New Products Ahead of 2026 RSNA
RevealDx launches two new products, ReViewer and ReViz, ahead of the 2026 RSNA Annual Meeting to support lung nodule imaging and AI performance tracking.
RevealDx Announces New Products Ahead of 2026 Radiological Association of North America
*Seattle, WA - November 19, 2026 -* RevealDx, a leader in AI-powered lung nodule characterization and malignancy prediction, today announced the launch of two new products, ReViewer and ReViz, ahead of the 2026 Radiological Society of North America (RSNA) Annual Meeting.
ReViewer is a Diagnostic Quality image viewer optimized for the identification and quantification of lung nodules. ReViewer enables deployment of the RevealAI-LUNG product into any PACS system and optimizes Radiologist workflow.
The company also introduced ReViz, a quality assurance and practice management dashboard that allows healthcare providers to monitor and track AI performance.
"We are excited to deliver these software solutions, and are looking forward to demonstrating all of them at RSNA 2026." said Chris Wood, CEO of RevealDx. "We have invested heavily to ensure our products fit seamlessly into the radiology and billing workflow. Our goal is to reduce reading time while simultaneously integrating billable AI products."
The announcement follows RevealDx's recent announcement that its new lung cancer screening CADx product, RevealAI-Screen, will be made available at no charge to U.S. patients (pending FDA clearance). Earlier this year, RevealDx also announced FDA clearance for RevealAI-Lung for use with incidentally detected lung nodules. The company received Medical Device Regulation (MDR) certification in November 2025 and has since deployed its technology at several institutions across the U.S. and Europe.
RevealDx customers can continue to choose to use any 3rd party nodule detector and nodule management system. To learn more about RevealDx and RevealAI-Screen, please visit https://reveal-dx.com/.
About RevealDx
RevealDx has developed RevealAI-Lung, the only Medical Imaging CADx software that can be deployed directly into Radiology workflow with (or without) a CADe detector. The company has published several studies demonstrating significant improvement in both early cancer detection as well as reduction in false positives. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. For more information, contact sales@reveal-dx.com.
Notes to editors
- Organisation
- RevealDx
- Contact
- Devyn Barnes
- Website
- https://reveal-dx.com/
Contact details are hidden from automated harvesters. Click to show them.